|  | 
    
  
    | 
| Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board  http://www.sources.com/Releases/NR1180.htmSources News Release
 Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
 Date Written:  23/02/2011
 Year Published:  2011
 Resource Type:  Article
 
 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product
 
 Abstract:  Hoboken, NJ  February 23, 2011 -- Anavex Life Sciences Corp. (Anavex, AVXL.OB) today announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert.  The SAB works closely with the company to support development of the Anavex product pipeline, including its lead compound ANAVEX 2-73, which is being studied for Alzheimers disease and is scheduled to enter Phase I clinical trials shortly.  Dr. Doody is the second clinical expert serving on the Anave...
 To read the full release go to http://www.sources.com/Releases/NR1180.htm
 
 Topics | 
 
 
	    	AlterLinksc/o Sources
 
 
 
 
© 2025.
 | 
    |  | 
 
       
 |  |